JY
URGN icon

Jeff Yass’s UroGen Pharma URGN Stock Holding History

Jeff Yass’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Sell
6,782
-76,841
-92% -$2.08M ﹤0.01% 11467
2026
Q1 		$1.5M Sell
83,623
-79,102
-49% -$1.59M ﹤0.01% 6868
2025
Q4 		$3.81M Buy
162,725
+15,500
+11% +$336K ﹤0.01% 4485
2025
Q3 		$2.94M Sell
147,225
-337,598
-70% -$6.06M ﹤0.01% 5011
2025
Q2 		$6.64M Buy
484,823
+392,798
+427% +$3.77M ﹤0.01% 3480
2025
Q1 		$1.02M Buy
92,025
+51,892
+129% +$553K ﹤0.01% 7222
2024
Q4 		$427K Buy
40,133
+3,118
+8% +$37.3K ﹤0.01% 9056
2024
Q3 		$470K Sell
37,015
-59,330
-62% -$881K ﹤0.01% 8600
2024
Q2 		$1.62M Buy
96,345
+68,934
+251% +$981K ﹤0.01% 5504
2024
Q1 		$411K Buy
27,411
+683
+3% +$11.2K ﹤0.01% 8968
2023
Q4 		$401K Buy
26,728
+6,553
+32% +$85.1K ﹤0.01% 9175
2023
Q3 		$283K Buy
20,175
+7,441
+58% +$119K ﹤0.01% 9484
2023
Q2 		$132K Sell
12,734
-186,699
-94% -$2.06M ﹤0.01% 10702
2023
Q1 		$1.84M Buy
199,433
+160,461
+412% +$1.48M ﹤0.01% 5311
2022
Q4 		$346K Buy
+38,972
New +$369K ﹤0.01% 8753
2021
Q2 		– Sell
-14,580
Closed -$284K – 13290
2021
Q1 		$284K Sell
14,580
-566
-4% -$12K ﹤0.01% 10727
2020
Q4 		$273K Sell
15,146
-23,150
-60% -$485K ﹤0.01% 9456
2020
Q3 		$739K Sell
38,296
-48,411
-56% -$1.1M ﹤0.01% 6846
2020
Q2 		$2.27M Sell
86,707
-6,403
-7% -$156K ﹤0.01% 4280
2020
Q1 		$1.66M Sell
93,110
-9,335
-9% -$252K ﹤0.01% 4315
2019
Q4 		$3.42M Buy
102,445
+47,916
+88% +$1.31M ﹤0.01% 3496
2019
Q3 		$1.3M Buy
54,529
+46,749
+601% +$1.53M ﹤0.01% 5134
2019
Q2 		$280K Buy
+7,780
New +$287K ﹤0.01% 8459
2018
Q4 		– Sell
-5,141
Closed -$231K – 10014
2018
Q3 		$243K Buy
+5,141
New +$239K ﹤0.01% 7872

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jeff Yass's URGN Position: Q2 2026 in Review

Jeff Yass reduced its UroGen Pharma (URGN) stake by 92% in Q2 2026, selling an estimated $2.08M and leaving 6,782 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #11467.

Jeff Yass first reported a position in URGN in Q3 2018 and has held it in 24 quarters since. The position peaked at $6.64M in Q2 2025. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Jeff Yass held 6,782 shares of UroGen Pharma worth $250K as of Q2 2026.
  • Jeff Yass sold 76,841 UroGen Pharma shares in Q2 2026, an estimated $2.08M.
  • UroGen Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11467 holding.
  • Jeff Yass first reported a position in UroGen Pharma in Q3 2018 and has held it in 24 quarters since.
  • Jeff Yass's UroGen Pharma position peaked at $6.64M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.